Article de Périodique
Predictors of abstinence maintenance after cocaine inpatient detoxification: A prospective study (2024)
Auteur(s) :
POIREAU, M. ;
CLERGUE-DUVAL, V. ;
MAILLARD, A. ;
ICICK, R. ;
AZUAR, J. ;
SMITH, P. ;
FAURENT, M. ;
VOLLE, E. ;
DELMAIRE, C. ;
CABÉ, J. ;
BLOCH, V. ;
VORSPAN, F.
Année
2024
Page(s) :
576-582
Langue(s) :
Anglais
Refs biblio. :
30
Domaine :
Drogues illicites / Illicit drugs
Thésaurus géographique
FRANCE
Thésaurus mots-clés
ETUDE PROSPECTIVE
;
COCAINE
;
DESINTOXICATION
;
ABSTINENCE
;
FACTEUR PREDICTIF
;
ETUDE CLINIQUE
;
HOSPITALISATION
;
DUREE
;
TRAITEMENT
;
VOIE D'ADMINISTRATION
Résumé :
BACKGROUND AND OBJECTIVES: Cocaine is a highly addictive substance, and with no approved medication for cocaine use disorder (CUD), leading to a heavy burden. Despite validated psychosocial treatments, relapse rates after detoxification are very high in CUD. Few consistent factors can predict abstinence after detoxification. Our study, therefore, aimed at identifying factors predicting abstinence among CUD patients after inpatient detoxification.
METHODS: Eighty-one CUD inpatients were included during detoxification and characterized for clinical and sociodemographic data at baseline and at a follow-up of 3 months after discharge, including a standard measure of their abstinence duration from cocaine. We performed Cox univariate analyzes to determine the factors associated with abstinence maintenance, followed by a multivariate Cox regression to identify independent predictors.
RESULTS: Abstinence maintenance was shorter in patients injecting cocaine (hazard ratio [HR] = 5.16, 95% confidence interval [CI]: 2.01-13.27, p < .001) and using cocaine heavily in the month before inclusion (HR = 1.03, 95% CI: 1.00-1.06, p = .046). Conversely, abstinence maintenance was longer in patients with longer inpatient detoxification stays (HR = 0.96, 95% CI: 0.94-0.99, p = .015) and prescribed with selective serotonin reuptake inhibitors (SSRIs) (HR = 0.30, 95% CI: 0.16-0.56, p < .001).
DISCUSSION AND CONCLUSIONS: Patients with severe CUD may require longer inpatient stays to achieve abstinence. Regarding SSRI prescription, more specific studies are needed to provide stronger recommendations about their use in clinical practice.
SCIENTIFIC SIGNIFICANCE: Our findings suggest several modifiable factors to improve inpatient treatment response in CUD. As there are no specific recommendations about the optimal duration of inpatient stay, our results could pave the way for evidence-based guidelines.
METHODS: Eighty-one CUD inpatients were included during detoxification and characterized for clinical and sociodemographic data at baseline and at a follow-up of 3 months after discharge, including a standard measure of their abstinence duration from cocaine. We performed Cox univariate analyzes to determine the factors associated with abstinence maintenance, followed by a multivariate Cox regression to identify independent predictors.
RESULTS: Abstinence maintenance was shorter in patients injecting cocaine (hazard ratio [HR] = 5.16, 95% confidence interval [CI]: 2.01-13.27, p < .001) and using cocaine heavily in the month before inclusion (HR = 1.03, 95% CI: 1.00-1.06, p = .046). Conversely, abstinence maintenance was longer in patients with longer inpatient detoxification stays (HR = 0.96, 95% CI: 0.94-0.99, p = .015) and prescribed with selective serotonin reuptake inhibitors (SSRIs) (HR = 0.30, 95% CI: 0.16-0.56, p < .001).
DISCUSSION AND CONCLUSIONS: Patients with severe CUD may require longer inpatient stays to achieve abstinence. Regarding SSRI prescription, more specific studies are needed to provide stronger recommendations about their use in clinical practice.
SCIENTIFIC SIGNIFICANCE: Our findings suggest several modifiable factors to improve inpatient treatment response in CUD. As there are no specific recommendations about the optimal duration of inpatient stay, our results could pave the way for evidence-based guidelines.
Affiliation :
Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, APHP, Paris, France.
Université Paris Cité, UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, INSERM, Paris, France.
FHU NOR-SUD (Network of Research in Substance Use Disorders), APHP, Paris, France.
FRONT-Lab, ICM Institut du Cerveau, INSERM, Paris, France.
Service de Neuroradiologie, Fondation Ophtalmologique Rothschild, Paris, France.
Clermont Auvergne INP, CHU Clermont-Ferrand, CNRS, Institut Pascal, Université Clermont Auvergne, Clermont-Ferrand, France.
Service de Pharmacie à Usage Interne, Hôpital Fernand Widal, APHP, Paris, France.
Université Paris Cité, UMR-S 1144 Therapeutic Optimization in Neuropsychopharmacology, INSERM, Paris, France.
FHU NOR-SUD (Network of Research in Substance Use Disorders), APHP, Paris, France.
FRONT-Lab, ICM Institut du Cerveau, INSERM, Paris, France.
Service de Neuroradiologie, Fondation Ophtalmologique Rothschild, Paris, France.
Clermont Auvergne INP, CHU Clermont-Ferrand, CNRS, Institut Pascal, Université Clermont Auvergne, Clermont-Ferrand, France.
Service de Pharmacie à Usage Interne, Hôpital Fernand Widal, APHP, Paris, France.
Historique